Rebiotix Clinical, Microbiome Data from First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018

New data continues to underscore company leadership in microbiome field


Download this press release (241 KB).

ROSEVILLE, MN – OCTOBER 01, 2018 — Rebiotix Inc., part of the Ferring Pharmaceuticals Group, announced today that data new from their Microbiota Restoration Therapy™ (MRT) drug development platform will be presented at the annual Infectious Disease conference, which will be held October 3-7 in San Francisco.

Each data set highlights the company’s continued leadership in the microbiome field, providing new insight into the durability of RBX2660 months after use as treatment in their recent Open-Label trial, to be presented by Rebiotix’s Associate Director of Clinical Research, Sarah Mische, PhD. Additionally, the company will share findings from the novel application of their Microbiome Health Index™, which has been developed as platform to quantify changes in patient microbiome profiles; Rebiotix’s Chief Scientific Officer, Ken Blount, PhD, will present the latest developments.

The schedule of poster presentations is as follows:

Investigators:

S. Mische, R. Orenstein, E. Dubberke, S. Khanna, G. Hecht, H. Dupont, C. Lee, K. Blount

Poster Information:

No. 1950, October 6; 12:30 PM – 1:45 PM PT

Track & Location:

“Clinical Trials,” S Poster Hall

Investigators:

K. Blount, C. Jones, E. Deych, B. Shannon

Poster Information:

No. 1966, October 6; 12:30 PM – 1:45 PM PT

Track & Location:

“Clinical Trials,” S Poster Hall


About Rebiotix Inc.

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized non-frozen, oral capsule formulation, which is currently the subject of an investigator-sponsored Phase 1 trial for the prevention of recurrent C. diff infection. In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ platform. The MRT platform is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalized healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. Learn more at www.ferring.com.


Rebiotix Media Contact:

Courtney Jones
651-705-8774
cjones@nullrebiotix.com